Vinorelbine and ifosfamide for unresectable non-small cell lung cancer

Lung Cancer

Volumn 18, Issue 1, 1997, Pages 95-100

  Morere, J F ^a   Piperno neumann, S ^a   Brunet, A ^a   Boaziz, C ^a   Kohn, M ^a   Bouillet, T ^a   Breau, J L ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Chemotherapy; Ifosfamide; Non small cell lung cancer; Vinorelbine

Indexed keywords

IFOSFAMIDE; MESNA; METHYLPREDNISOLONE; NAVELBINE; ONDANSETRON;

ADULT; AGED; ARTICLE; BRAIN DISEASE; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MIDDLE AGED; VINBLASTINE;

EID: 0030844609     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00044-5     Document Type: Article

References (25)

1. Minna JO, Higgins GA, Glatstein EJ. Cancer of the lung. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology, Philadelphia-Toronto: J.B. Lippincott, 1982:396-474.
2. Cojean I, Le Chevalier T. Chemotherapy of stage IIIB and IV non-small cell lung cancer. Ann Oncol 1995;6:S41-4.
3. Souhami RL, Stewart LA, Arriagada R, et al. A data-based meta-analysis of randomised trials of chemotherapy versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1994;11:24-5.
4. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
5. Thatcher N, Ranson M, Lee SM, Niven R, Anderson H. Chemotherapy in non-small cell lung cancer. Ann Oncol 1995;6:S83-95.
6. Carney DN, Byrne A. Treatment of the elderly small cell lung cancer patient. Lung Cancer 1994;11:230-1.
7. Ettinger DS. Ifosfamide in the treatment of non-small cell lung cancer. Sem Oncol 1989;16:31-8.
8. Depierre A, Lemarie E, Dabouis G, et al. Phase II study of navelbine (NVB) in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1988;7:778.
9. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9.
10. Yokoyama A, Furuse K, Niitani H, et al. Multi-institutional phase II study of navelbine (vinorelbine) in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1992;11:957.
11. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized Study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a european multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
12. Depierre A, Chastang CI, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994;5:37-42.
13. Berthaud P, Le Chevalier T, Ruffie P, et al. Phase I-II study of vinorelbine (navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992;28A:1863-5.
14. Palackdharry CS, Krigel RL. Dose-intensive Ifosfamide/carboplatin/etoposide plus granylocytemacrophage colony stimulating factor for non-small cell lung cancer. Sem Oncol 1994;21:6-11.
15. Baldini E, Tibaldi C, Chella A, et al. Combination chemotherapy with vinorelbine, ifosfamide and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer. Semin Oncol 1994;21:12-5.
16. Cullen MH, Mitomycin, ifosfamide and cisplatin in Non-small Cell Lung Cancer. Oncology 1993;50 Suppl.:31-34.
17. Vafai D, Israel V, Zaretski S, et al. Phase I/II trial of combination carboplatin and taxol in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1995;14:352.
18. Rowinsky EK, Sartorius SE, Bowling SE, et al. Paclitaxel as a 3-hour Schedule and carboplatin in non-small cell lung cancer: use of maximally tolerated and clinically relevant single agent doses in combination is feasible [abstract]. Proc Am Soc Clin Oncol 1995;14:354.
19. Lange CJ, Leighton J, Comis R, et al. Paclitaxel and carboplatin in advanced non-small cell lung cancer: toxicity, response and survival update [abstract]. Proc Am Soc Clin Oncol 1995;14:355.
20. Alonso JL, et al. Ifosfamide encephalopathy and methylene-blue: a case report. Ann Oncol 1996;7(6):643-5.
21. Harpey JP, Charpentier C, Coude M. Methylene-blue for riboflavin-unresponsive glutaricaciduria type II. The Lancet 1986;1(February 15):391.
22. Karnycheff F, et al. Bleu de methylène. In: Husson MC, editor. Dossier du CNIMH-Revue d'Evaluation sur le Médicament. Paris: Centre National d'Information sur le Médicament Hospitalier, 1995:16-30.
23. Küpfer A, et al. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994;343(March 26):763-4.
24. Küpfer C, Aeschlimann C, Cerny T. Methylene-blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Europ J of Clin Pharmacol 1996;50(4):249-52.
25. Zulian GB, Tullen E, Maton B. Methylene-blue for ifosfamide associated encephalopathy. New Engl J Med 1995;332(18):1239-40.